Otsuka Holdings Co., Ltd. Provides Consolidated Earnings Guidance for Second Quarter and Year Ending December 31, 2023
May 12, 2023 at 12:30 am EDT
Share
Otsuka Holdings Co., Ltd. provided consolidated earnings guidance for second quarter (YTD) and year ending December 31, 2023. For the quarter, the company expected Revenue of JPY 867,000 million, operating profit of JPY 91,500 million, Profit for the year of JPY 70,000 million, Profit attributable to owners to be JPY 68,000. Basic earnings per share of JPY 125.31 per basic share.
For the year, the company expected Revenue of JPY 1,800,000 million, operating profit of JPY 210,000 million, Profit for the year of JPY 161,500 million, Profit attributable to owners to be JPY 157,500. Basic earnings per share of JPY 290.25 per basic share.
Otsuka Holdings Co, Ltd. is a holding company organised around 4 areas of activity:
- manufacture and sale of pharmaceutical products (65.2% of sales): prescription drugs and intravenous solutions mainly for the treatment of central nervous system disorders, cancer, cardiovascular, gastrointestinal and ophthalmic diseases. In addition, the group sells diagnostic products and medical devices;
- manufacture and sale of nutraceutical products (25.1%): functional foods and beverages, OTC products, nutritional supplements;
- production of mineral waters, beverages and foods (2.1%);
- other (7.5%): manufacture of functional chemicals and fine chemicals, provision of logistics services, manufacture of electronic products, etc.
Net sales by source of income are divided between sales of products (93.8%), sales of licences and royalties (1.8%) and other (4.4%).
Net sales are distributed geographically as follows: Japan (43.2%), North America (34%),
OTSUKA HOLDINGS CO., LTD. 
